2021
Association of pathological complete response rates and TILs in triple-negative breast cancer patients.
Kassem M, Goldstein D, Schnell P, Grimm M, Quiroga D, Miah A, Vargo C, Shinde N, Michael B, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai S, Wesolowski R, Lustberg M, Ramaswamy B, Tozbikian G, Cherian M. Association of pathological complete response rates and TILs in triple-negative breast cancer patients. Journal Of Clinical Oncology 2021, 39: e12596-e12596. DOI: 10.1200/jco.2021.39.15_suppl.e12596.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesInternational TILs Working GroupPathological complete response rateComplete response rateNeoadjuvant chemotherapyLong-term prognosisTNBC patientsBreast cancerAssociation of TILsResponse rateHigh distant recurrence rateOhio State University Comprehensive Cancer CenterTriple-negative breast cancer patientsSingle-institution retrospective analysisHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Residual cancer burden indexRates of breastDistant recurrence ratesPreoperative systemic therapyGrowth factor receptor 2Majority of patientsInvasive ductal cancerBreast cancer patientsTriple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHuman epidermal growth factor receptor 2Vascular endothelial growth factorHomologous recombination deficiencyBreast cancerEpidermal growth factor receptorGrowth factor receptorPredictive biomarkersTreatment optionsFibroblast growth factor receptorManagement of TNBCEpidermal growth factor receptor 2Factor receptorGrowth factor receptor 2PI3K/Akt/mTORLimited treatment optionsNTRK gene fusionsFactor receptor 2Akt/mTOREndothelial growth factorCell-free DNAAntibody-drug conjugatesClinical outcomesImmune biomarkersPoor prognosisTreating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSodium-glucose co-transporter-2 inhibitorsLow-carbohydrate dietCase seriesCarbohydrate dietHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Sodium-Glucose CoTransporter 2 inhibitorsTarget adverse effectsFactor receptor 2Postmenopausal womenTreatment delayPharmacologic interventionsBreast cancerDose reductionReceptor 2HyperglycemiaTreatment efficacyHormone receptorsAdverse effectsAlpelisibSelective phosphatidylinositolTherapy
2015
Palbociclib
Mangini N, Wesolowski R, Ramaswamy B, Lustberg M, Berger M. Palbociclib. Annals Of Pharmacotherapy 2015, 49: 1252-1260. PMID: 26324355, PMCID: PMC7331461, DOI: 10.1177/1060028015602273.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclin-Dependent KinasesDisease-Free SurvivalEstradiolFemaleFulvestrantHumansLetrozoleNeoplasms, Hormone-DependentNitrilesPiperazinesPyridinesRandomized Controlled Trials as TopicReceptor, ErbB-2TriazolesUnited StatesConceptsProgression-free survivalAdvanced breast cancerInvestigator-assessed median progression-free survivalMedian progression-free survivalPhase III trialsBreast cancerEndocrine therapyIII trialsOncology abstractsHER2-negative advanced breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Negative advanced breast cancerConfirmatory phase III trialClinical Oncology abstractsMedical Oncology abstractsPALOMA-3 trialFirst-line settingPhase II trialGrowth factor receptor 2Drug Administration approvalFactor receptor 2Life-threatening diseaseCyclin-dependent kinase 4Novel small molecule inhibitor